Journal of the Neurological Sciences
Volume 206, Issue 2 , Pages 165-171 , 15 February 2003

Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease

References 

  1. Lassmann H. Neuropathology in multiple sclerosis: new concepts. Mult. Scler. 1998;4:93–98
  2. Trapp BD, Bö L, Mörk S, Chang A. Pathogenesis of tissue injury in MS lesions. J. Neuroimmunol. 1999;98:49–56
  3. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N. Engl. J. Med. 2000;343:938–952
  4. Charcot M. Histologie de le sclerose en plaques. Gaz. Hop. 1868;141:554–558
  5. Kornek B, Lassmann H. Axonal pathology in multiple sclerosis: a historical note. Brain Pathol. 1999;9:651–656
  6. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain. 1997;120:393–399
  7. Trapp BD, Peterson J, Ransohoff RM, et al.  Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 1998;338:278–285
  8. Kornek B, Storch MK, Weissert R, et al.  Multiple sclerosis and chronic autoimmune encephalomyelitis. A comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am. J. Pathol. 2000;157:267–276
  9. Lu F, Selak M, O'Connor J, et al.  Oxidative damage to mitochondrial DNA and activity of mitochondrial enzymes in chronic active lesions of multiple sclerosis. J. Neurol. Sci. 2000;177:95–103
  10. Pitt D, Werner P, Raine CS. Glutamate excitotoxicity in a model of multiple sclerosis. Nat. Med. 2000;6:67–70
  11. Babbe H, Roers A, Waisman A, et al.  Clonal expansions of CD8+ T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J. Exp. Med. 2000;192:393–404
  12. Huseby ES, Liggitt D, Brabb T, et al.  A pathogenic role for myelin-specific CD8+ T cells in a model for multiple sclerosis. J. Exp. Med. 2001;194:669–676
  13. Medana I, Martinic MA, Wekerle H, Neumann H. Transection of major histocompatibility complex class I-induced neurites by cytotoxic T lymphocytes. Am. J. Pathol. 2001;159:809–815
  14. Smith KJ, Kapoor R, Hall SM, Davies M. Electrically active axons degenerate when exposed to nitric oxide. Ann. Neurol. 2001;49:470–476
  15. Shi R, Blight AR. Compression injury of mammalian spinal cord in vitro and the dynamics of action potential conduction failure. J. Neurophysiol. 1996;76:1572–1580
  16. Wujek JR, Bjartmar C, Richer E, et al.  Axon loss in the spinal cord determines permanent neurological disability in an animal model of multiple sclerosis. J. Neuropathol. Exp. Neurol. 2002;61:23–32
  17. Ganter P, Prince C, Esiri MM. Spinal cord axonal loss in multiple sclerosis: a post-mortem study. Neuropathol. Appl. Neurobiol. 1999;25:459–467
  18. Lovas G, Szilagyi N, Majtenyi K, et al.  Axonal changes in chronic demyelinated cervical spinal cord plaques. Brain. 2000;123:308–317
  19. Evangelou N, Esiri MM, Smith S, et al.  Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis. Ann. Neurol. 2000;47:391–395
  20. Bjartmar C, Kinkel RP, Kidd G, et al.  Axonal loss in normal-appearing white matter in a patient with acute MS. Neurology. 2001;57:1248–1252
  21. Simon JH, Kinkel RP, Jacobs L, et al.  A Wallerian degeneration pattern in patients at risk for MS. Neurology. 2000;54:1155–1160
  22. Bjartmar C, Kidd G, Mörk S, et al.  Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann. Neurol. 2000;48:893–901
  23. Coles AJ, Wing MG, Molyneux P, et al.  Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann. Neurol. 1999;46:296–304
  24. Rudick RA, Goodman A, Herndon RM, Panitch HS. Selecting relapsing remitting multiple sclerosis patients for treatment: the case for early treatment. J. Neuroimmunol. 1999;98:22–28
  25. Bjartmar C, Yin X, Trapp BD. Axonal pathology in myelin disorders. J. Neurocytol. 1999;28:383–395
  26. Scherer S. Axonal pathology in demyelinating diseases. Ann. Neurol. 1999;45:6–7
  27. Yin X, Crawford TO, Griffin JW, et al.  Myelin-associated glycoprotein is a myelin signal that modulates the caliber of myelinated axons. J. Neurosci. 1998;18:1953–1962
  28. Griffiths I, Klugmann M, Anderson T, et al.  Axonal swellings and degeneration in mice lacking the major proteolipid of myelin. Science. 1998;280:1610–1613
  29. Waxman SG. Acquired channelopathies in nerve injury and MS. Neurology. 2001;56:1621–1627
  30. Waxman SG. Demyelinating diseases—new pathological insights, new therapeutic targets. N. Engl. J. Med. 1998;338:223–225
  31. Bjartmar C, Trapp BD. Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr. Opin. Neurol. 2001;14:271–278
  32. Reddy H, Narayanan S, Arnoutelis R, et al.  Evidence for adaptive functional changes in the cerebral cortex with axonal injury from multiple sclerosis. Brain. 2000;123:2314–2320
  33. Gonen O, Catalaa I, Babb JS, et al.  Total brain N-acetylaspartate: a new measure of disease load in MS. Neurology. 2000;54:15–19
  34. De Stefano N, Matthews PM, Fu L, et al.  Axonal damage correlates with disability in patients with relapsing–remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain. 1998;121:1469–1477
  35. Fu L, Matthews PM, De Stefano N. Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain. 1998;121:103–113
  36. Matthews PM, De Stefano N, Narayanan S, et al.  Putting magnetic resonance spectroscopy studies in context: axonal damage and disability in multiple sclerosis. Semin. Neurol. 1998;18:327–336
  37. Trapp BD, Ransohoff RM, Fisher E, Rudick RA. Neurodegeneration in multiple sclerosis: relationship to neurological disability. Neuroscientist. 1999;5:48–57
  38. Lloyd KG. CNS compensation to dopamine neuron loss in Parkinson's disease. Adv. Exp. Med. Biol. 1977;90:255–266
  39. Bradley WG. Recent views on amyotrophic lateral sclerosis with emphasis on electrophysiological studies. Muscle Nerve. 1987;10:490–502
  40. Yu M, Nishiyama A, Trapp BD, Tuohy V. Interferon-β inhibits progression of relapsing–remitting experimental autoimmune encephalomyelitis. J. Neuroimmunol. 1996;64:91–100
  41. Altin JG, Sloan EK. The role of CD45 and CD45-associated molecules in T cell activation. Immunol. Cell Biol. 1997;75:430–445
  42. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N. Engl. J. Med. 2000;343:1430–1438
  43. Brownell B, Hughes JT. The distribution of plaques in the cerebrum in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 1962;25:315–320
  44. Lumsden CE. The neuropathology of multiple sclerosis. In:  Vinken PJ,  Bruyn GW editor. Handb. Clin. Neurol. vol. 9:Amsterdam: North-Holland; 1970;p. 217–309
  45. Kidd D, Barkhof F, McConnell R, et al.  Cortical lesions in multiple sclerosis. Brain. 1999;122:17–26
  46. Peterson JW, Bö L, Mörk S, et al.  Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann. Neurol. 2001;50:389–400
  47. Sharma R, Narayana PA, Wolinsky JS. Grey matter abnormalities in multiple sclerosis: proton magnetic resonance spectroscopic imaging. Mult. Scler. 2001;7:221–226
  48. Filippi M. Multiple sclerosis: a white matter disease with associated gray matter damage. J. Neurol. Sci. 2001;185:3–4
  49. Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis: I. Frequency, patterns, and prediction. Neurology. 1991;41:685–691
  50. Beatty WW, Paul RH, Wilbanks SL, et al.  Identifying multiple sclerosis patients with mild or global cognitive impairment using the Screening Examination for Cognitive Impairment (SEFCI). Neurology. 1995;45:718–723
  51. Blinkenberg M, Rune K, Jensen CV, et al.  Cortical cerebral metabolism correlates with MRI lesion load and cognitive dysfunction in MS. Neurology. 2000;54:558–564

PII: S0022-510X(02)00069-2

Journal of the Neurological Sciences
Volume 206, Issue 2 , Pages 165-171 , 15 February 2003

Article Tools

* Image Usage & Resolution